Search results
Showing 1 to 50 of 8099 results
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Tell us about an interventional procedure you think should be assessed by NICE.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....
View recommendations for HTE18Show all sections
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
Embed NICE content in your digital products and services with our syndication API
Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.
Our methods and processes (health technology evaluation manual)
Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...
Costs: charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS. Browse technology...
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
NICE executive team meeting minutes and agenda
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA966
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients.
The BNF aims to provide prescribers, pharmacists, and other healthcare professionals with sound up-to-date information about the use of medicines. The
The latest gender pay gap data from NICE
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...
This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women and people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for IPG785Show all sections
Please note, from April 2023 NICE will no longer produce or maintain Medtech Innovation Briefings (MIBs) on behalf of NHS England. MIBs were...
NICE research projects and partners.
The quality standards advisory committees (QSAC) are independent committees that help to develop our quality standards . Come to a meeting Committee
Details, meeting dates and minutes of the independent technology appraisal committees
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia
170,000 people in England to have further treatment choice for preventing migraine attacks.
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.
Biographies of the NICE executive team and minutes of their meetings
Find out more about NICE technology appraisals advisory committee D members
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
Help us improve NICE: take part in research to help us develop better products and services.
We want to better understand views and experiences of NICE, from our audiences.
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
Technology appraisal submission templates and supporting documents
On this page, you'll find all the templates and supporting documents you need to make a technology appraisals submission. These templates have been...
We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms. From this page, you can find
A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.
On this page, you'll find all our modular updates relating to our technology appraisal guidance. October 2023 NICE response to consultation on the...
1. Provisional appraisal topics chosen The NICE topic selection programme produces a list of provisional appraisal topics. 2. Stakeholders identified
On this page, you'll find a list of all our position statements relating to our technology appraisal guidance. Biosimilar technologies: NICE position
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Evidence-based recommendations on Kurin Lock for blood culture collection.
View recommendations for MTG77Show all sections